
Cassel Salpeter & Co.’s Q3 healthcare update points to disrupted NIH grant processing, FDA attrition, and tariffs as pressures on drug development and early-stage financing.
A perspective piece from the New England Journal of Medicine calls for improvements in trial design for biomedical HIV treatments.






